IQVIA Financial Model
Healthcare Services Company Financials Example (Free Excel Download)
IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
professionals from Deloitte
Used by professionals from
About this model
This model evaluates IQVIA's equity valuation and debt service capacity by forecasting clinical trial backlog conversion, healthcare data subscription renewals, and free cash flow allocation between debt repayment and share repurchases.
IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company was formed through the 2016 merger of Quintiles (a top-tier Contract Research Organisation) and IMS Health (a leading healthcare data and analytics provider).
Business segments include Research & Development Solutions (R&DS) contributing approximately 55% of revenue, Technology & Analytics Solutions (TAS) contributing approximately 41%, and Contract Sales & Medical Solutions (CSMS) contributing approximately 4%. The company operates globally, with the Americas generating roughly 50% of revenue, EMEA 30%, and Asia-Pacific 20%. IQVIA employs an asset-light, data-rich business model, leveraging its proprietary CORE database (over 1.2 billion non-identified patient records) to accelerate clinical trials and commercialise drugs. Its competitive position is dominant, ranking as a top-two global CRO alongside ICON plc, and holding a near-monopoly in certain global healthcare data assets, competing with Veeva Systems in life sciences software. Recent major events include continuous bolt-on acquisitions in the analytics space and navigating post-pandemic normalisation in clinical trial funding.
The downloadable IQVIA financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsIQVIA financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $13.87B | $14.41B | $14.98B | $15.40B | $16.31B |
| Cost of revenues, exclusive of depreciation and amortization | $9.23B | $9.38B | $9.74B | $10.03B | $10.88B |
| Operating income | $1.39B | $1.80B | $1.98B | $2.20B | $2.18B |
| Net income | $966.0M | $1.09B | $1.36B | $1.37B | $1.36B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for IQVIA
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Research & Development Solutions (R&DS)
- Segment name: Research & Development Solutions
- Revenue driver formula: Beginning Backlog x Backlog Conversion Rate + Pass-Through Revenues
- Historical growth rate: 6% to 10% CAGR
- Key growth levers and headwinds: Biotech funding environments, large pharma R&D outsourcing trends, and decentralised clinical trial adoption.
- Pricing dynamics: Contractual, milestone-based pricing with pass-through costs billed at zero margin.
- Revenue recognition notes: Recognised over time using the percentage-of-completion method based on costs incurred relative to total estimated costs.
- Seasonality: Q4 is typically the strongest quarter for bookings (Net New Business) due to pharma year-end budget flushes.
Technology & Analytics Solutions (TAS)
- Segment name: Technology & Analytics Solutions
- Revenue driver formula: Prior Year Recurring Revenue x Net Retention Rate + New Software/Data Sales + Consulting Engagements
- Historical growth rate: 5% to 8% CAGR
- Key growth levers and headwinds: Migration to cloud-based SaaS solutions, demand for real-world evidence (RWE), and pharma commercial budget constraints.
- Pricing dynamics: Subscription-based for data and SaaS, time-and-materials for consulting.
- Revenue recognition notes: SaaS and data subscriptions are recognised rateably over the contract term; consulting is recognised as services are delivered.
- Seasonality: Q4 shows a slight uptick in consulting delivery and software implementations.
Contract Sales & Medical Solutions (CSMS)
- Segment name: Contract Sales & Medical Solutions
- Revenue driver formula: Number of Contracted Representatives x Revenue per Representative
- Historical growth rate: Flat to declining (negative 2% to 1% CAGR)
- Key growth levers and headwinds: Pharma shifting away from massive primary care sales forces towards targeted specialty drug launches.
- Pricing dynamics: Highly competitive, lower-margin contractual agreements.
- Revenue recognition notes: Recognised over time as personnel services are provided.
- Seasonality: Generally stable throughout the year.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Direct costs of clinical trials (investigator grants, patient recruitment), data acquisition costs, software hosting fees, and delivery headcount salaries.
- Gross margin range: 33% to 35% historically.
- Key input costs and commodity exposures: Highly exposed to specialised clinical and IT labour wage inflation; data acquisition licensing fees.
- How COGS scales with revenue: R&DS direct costs scale linearly, but pass-through costs carry zero margin, meaning revenue mix heavily dictates consolidated gross margin percentages. TAS data costs have high operating leverage.
Operating Expenses
- R&D: Not reported as a separate major line item; software development costs are largely capitalised or absorbed into cost of revenues.
- SG&A: Typically 10% to 12% of revenue. Includes corporate overhead, global sales force, and administrative functions. Largely headcount-driven.
- Depreciation & Amortisation: Extremely high (8% to 10% of revenue) due to the massive intangible asset base created by the Quintiles/IMS merger and subsequent acquisitions.
- Stock-Based Compensation: Typically 1.5% to 2.5% of revenue, a material non-cash expense that must be added back for Adjusted EBITDA calculations.
- Restructuring / one-time charges: Frequent but moderate (0.5% to 1.0% of revenue), usually tied to facility consolidations and workforce realignments following acquisitions.
Margin Profile
- Gross margin: 33% to 35%.
- Adjusted EBITDA margin: 23% to 24.5% (expanding slowly).
- Operating margin (GAAP): 11% to 13% (depressed by heavy amortisation).
- Net margin (GAAP): 7% to 9%.
- Margin trend: Adjusted margins are slowly expanding due to a mix shift towards the higher-margin TAS segment and operating leverage in data assets.
Balance Sheet Structure
- Total assets: Approximately $24 billion to $26 billion.
- Key asset categories: Goodwill and intangible assets dominate the balance sheet. Accounts receivable and unbilled services are the primary current assets.
- Goodwill & intangibles as % of total assets: Typically 65% to 70%, reflecting the company's acquisitive history.
- Working capital profile:
- Days Sales Outstanding (DSO): 45 to 55 days.
- Days Inventory Outstanding (DIO): Not applicable.
- Days Payable Outstanding (DPO): 50 to 60 days.
- Net working capital as % of revenue: Slightly positive but tightly managed.
- Is working capital positive or negative? Generally positive. Unbilled services (contract assets) often exceed unearned income (contract liabilities).
- PP&E: Very light (around 2% to 3% of total assets), consisting mainly of IT hardware and leasehold improvements.
- Right-of-use assets / operating leases: Material but manageable, representing global office and laboratory space.
Capital Expenditure & Investment
- Capex as % of revenue: 3.5% to 4.5%.
- Maintenance capex vs. growth capex: Approximately 40% maintenance (IT refresh, facilities) and 60% growth (capitalised software development for new SaaS products).
- Major capex programmes underway or planned: Continuous investment in the proprietary CORE database and clinical trial management software platforms.
- Capitalised software / development costs: Highly material; a significant portion of total capex is internally developed software.
- M&A pattern: Serial bolt-on acquirer focusing on niche data sets, healthcare technology, and specialised clinical capabilities.
- Typical acquisition multiple paid: 12x to 15x EV/EBITDA for technology assets.
Debt & Capital Structure
- Total debt: Approximately $13 billion to $14 billion.
- Debt/EBITDA ratio: Target net leverage is 3.0x to 3.5x.
- Credit rating: Ba2/BB+ (high-yield / crossover).
- Key debt instruments: Senior secured term loans (Term Loan A and B), senior notes, and a revolving credit facility.
- Maturity profile: Well-laddered, with management actively refinancing near-term maturities to maintain a 4-to-5 year average duration.
- Interest rate profile: Historically a mix of fixed and floating, utilising interest rate swaps to manage floating rate exposure on term loans.
- Covenants: Standard secured net leverage ratio covenants on the credit facility.
- Share repurchase programme: Highly active. The company routinely allocates $1 billion to $1.5 billion annually to buybacks, absorbing most free cash flow.
- Dividend policy: No dividend. All return of capital is executed via share repurchases.
Cash Flow Characteristics
- Operating cash flow conversion: Strong, typically 1.5x to 2.0x of GAAP Net Income due to massive non-cash D&A add-backs.
- Free cash flow margin: 10% to 13% of revenue.
- Major non-cash items: Amortisation of intangibles, depreciation, stock-based compensation, and deferred income taxes.
- Working capital cash flow impact: Can be volatile quarter-to-quarter based on the timing of milestone payments from large pharma clients, but generally neutral over a full fiscal year.
- Capex intensity: Low, supporting high free cash flow conversion.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than the GAAP effective rate due to tax-deductible amortisation of goodwill from historical asset purchases.
Sheet Structure
- Assumptions: Hardcoded inputs for macroeconomic drivers, segment growth rates, margins, working capital days, and capital allocation policies.
- R&DS Backlog Schedule: Roll-forward of clinical trial backlog (Beginning Balance + Net New Business - Revenue = Ending Balance) and calculation of Book-to-Bill ratios.
- Income Statement: Segment-level revenue build (R&DS, TAS, CSMS), consolidated COGS, SG&A, D&A, Interest Expense, and GAAP to Non-GAAP reconciliations (Adjusted EBITDA, Adjusted Net Income).
- Balance Sheet: Assets (Cash, AR, Unbilled Services, PP&E, Goodwill, Intangibles), Liabilities (AP, Unearned Income, Current Debt, Long-Term Debt), and Shareholders' Equity.
- Cash Flow Statement: Operating, Investing, and Financing cash flows, explicitly linking D&A, SBC, working capital changes, capex, debt issuance/repayment, and share repurchases.
- Debt & Interest Schedule: Tranche-by-tranche debt roll-forward (Revolver, Term Loans, Senior Notes) calculating interest expense based on specific rates and average balances.
- Working Capital Schedule: Calculation of AR, AP, Unbilled Services, and Unearned Income based on DSO, DPO, and revenue/expense drivers.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value (Gordon Growth), and implied share price.
Key Financial Relationships
- `R&DS Net New Business = R&DS Revenue x R&DS Book-to-Bill Ratio`
- `Ending R&DS Backlog = Beginning R&DS Backlog + R&DS Net New Business - R&DS Revenue`
- `R&DS Revenue = Beginning R&DS Backlog x Quarterly Backlog Conversion Rate`
- `TAS Revenue = Prior Year TAS Revenue x (1 + TAS Revenue Growth Rate)`
- `CSMS Revenue = Prior Year CSMS Revenue x (1 + CSMS Revenue Growth Rate)`
- `Total Revenue = R&DS Revenue + TAS Revenue + CSMS Revenue`
- `Consolidated Gross Profit = Total Revenue x Gross Margin Percentage`
- `Adjusted EBITDA = Net Income + Provision for Income Taxes + Interest Expense + D&A + Stock-Based Compensation + Restructuring Costs`
- `Unbilled Services (Contract Assets) = (R&DS Revenue / 365) x Unbilled Days`
- `Unearned Income (Contract Liabilities) = (Total Revenue / 365) x Unearned Days`
- `Interest Expense = Average Total Debt x Weighted Average Interest Rate`
- `Share Repurchases = Free Cash Flow - Mandatory Debt Amortisation - Discretionary Debt Paydown`
- `Ending Basic Shares Outstanding = Beginning Shares - (Share Repurchases / Average Share Price)`
Cross-Sheet Dependencies
The Assumptions sheet feeds the R&DS Backlog Schedule and the revenue build on the Income Statement. Revenue drives the Working Capital Schedule, which calculates changes in operating assets and liabilities. These changes flow into the Cash Flow Statement to determine Operating Cash Flow. Operating Cash Flow minus Capex (from the Assumptions sheet) equals Free Cash Flow. Free Cash Flow dictates the cash available in the Debt & Interest Schedule for debt paydown or share repurchases. The ending debt balance feeds back into the Balance Sheet, and the calculated interest expense flows back up to the Income Statement. A circularity exists between Interest Expense, Net Income, Cash Flow, and Debt Balances; the builder must implement an interest circuit breaker (toggle) to prevent model corruption.
Sign Convention
- Income Statement: Revenue is positive. All expenses (COGS, SG&A, D&A, Interest, Taxes) are negative.
- Balance Sheet: All assets, liabilities, and equity balances are positive.
- Cash Flow Statement: Cash inflows (e.g., Net Income, D&A add-back, increase in AP, debt issuance) are positive. Cash outflows (e.g., increase in AR, capex, debt repayment, share repurchases) are negative.
- Backlog Schedule: Beginning backlog, net new business, and ending backlog are positive. Revenue deducted from backlog is negative.
Things Most Likely to Go Wrong
- Pass-through revenues in the R&DS segment carry zero gross margin. If the model assumes a flat consolidated gross margin while R&DS pass-throughs grow faster than TAS revenue, gross profit will be mathematically overstated.
- The R&DS backlog conversion rate is highly sensitive. A drop of just 50 basis points in the quarterly conversion rate can wipe out hundreds of millions in forecasted revenue.
- IQVIA reports heavily adjusted Non-GAAP metrics. The model must explicitly bridge GAAP Net Income to Adjusted EBITDA by adding back SBC, restructuring, and acquisition-related amortisation.
- Foreign currency translation significantly impacts reported revenue. The model should forecast on a constant-currency basis and apply a separate FX overlay if required.
- The company capitalises a large portion of its software development costs. This flatters operating cash flow at the expense of investing cash flow.
- Share repurchases are the primary driver of EPS growth. Failing to dynamically link free cash flow to share count reduction will severely understate future EPS.
- Unbilled services and unearned income are massive working capital items tied to clinical trial milestones. Modelling these strictly as a percentage of total revenue rather than R&DS revenue will cause working capital distortions.
- Interest expense is highly sensitive to floating rates on term loans. Ensure the debt schedule separates fixed notes from floating term loans.
Validation Checks
- R&DS Book-to-Bill ratio must remain above 1.1x to support mid-single-digit revenue growth; flag if it drops below 1.0x.
- Adjusted EBITDA margin should remain in the 23% to 25% range; flag if it exceeds 25% without a massive shift in TAS revenue mix.
- Net Leverage Ratio (Net Debt / Adjusted EBITDA) should remain between 3.0x and 4.0x; flag if it breaches 4.0x.
- Free Cash Flow conversion (FCF / Adjusted Net Income) should consistently track between 80% and 100%.
- The Balance Sheet must balance perfectly in all periods: Total Assets minus (Total Liabilities plus Shareholders' Equity) must equal zero.
- Capex as a percentage of revenue should not exceed 5.0% based on historical asset-light operations.
- The effective tax rate should remain between 18% and 22% absent major statutory corporate tax changes.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| R&DS Book-to-Bill Ratio | 1.25 | x | Historical average required to maintain R&DS backlog growth |
| R&DS Backlog Conversion Rate (Quarterly) | 9.5 | % | Recent historical average; reflects trial duration lengthening |
| TAS Revenue Growth Rate | 7.0 | % | Blended growth of SaaS adoption and data subscription renewals |
| CSMS Revenue Growth Rate | -1.0 | % | Reflects structural decline in traditional contract sales forces |
| Consolidated Gross Margin | 34.5 | % | 3-year historical average, balancing TAS growth and R&DS pass-throughs |
| SG&A as % of Revenue | 11.0 | % | Stable historical average reflecting scale efficiencies |
| D&A as % of Revenue | 8.5 | % | High rate driven by historical IMS/Quintiles merger intangibles |
| Stock-Based Comp as % of Revenue | 2.0 | % | Required add-back for Adjusted EBITDA reconciliation |
| Capex as % of Revenue | 4.0 | % | Historical average, largely capitalised software |
| Days Sales Outstanding (DSO) | 50 | Days | Based on historical accounts receivable balances |
| Days Payable Outstanding (DPO) | 55 | Days | Based on historical accounts payable balances |
| Effective Tax Rate | 20.0 | % | Management guidance and historical average |
| Weighted Average Interest Rate | 5.5 | % | Blended rate of fixed senior notes and floating term loans |
| Share Repurchase Allocation | 85.0 | % | Percentage of FCF after mandatory debt paydown directed to buybacks |
| WACC | 8.5 | % | Standard discount rate for a leveraged, large-cap healthcare IT firm |
| Terminal Growth Rate | 2.5 | % | Aligns with long-term global healthcare spending growth |
Data Sources & Benchmarks
- SEC EDGAR: IQVIA Holdings Inc. (CIK: 0001478242) 10-K and 10-Q filings.
- IQVIA Investor Relations website for quarterly earnings presentations and financial supplement spreadsheets.
- Key peers for benchmarking: ICON plc (ICLR), Veeva Systems (VEEV), Thermo Fisher Scientific (TMO - PPD segment), and Syneos Health (private).
- Industry data sources: EvaluatePharma for global R&D spend forecasts; Gartner for healthcare IT spending trends.
- Consensus estimates: Bloomberg or FactSet for forward-looking revenue and Adjusted EBITDA consensus to validate model outputs.
Sources
- IQVIA Holdings Inc. Form 10-K filed with the SEC (https://www.sec.gov/edgar/browse/?CIK=1478242)
- IQVIA Investor Relations Financial Supplements (https://ir.iqvia.com/financial-information/quarterly-results)
- ICON plc Form 20-F (for CRO industry benchmarking)
- Veeva Systems Form 10-K (for life sciences SaaS benchmarking)
Do more with the IQVIA model
Frequently asked
What services does IQVIA provide to the life sciences industry?+
IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences sector. The company leverages its proprietary CORE database, containing over 1.2 billion non-identified patient records, to accelerate clinical trials and commercialize drugs. Its business segments include Research & Development Solutions, Technology & Analytics Solutions, and Contract Sales & Medical Solutions.
How does IQVIA generate its revenue, and what are its primary business segments?+
IQVIA generates revenue primarily through its Research & Development Solutions (approximately 55%), Technology & Analytics Solutions (approximately 41%), and Contract Sales & Medical Solutions (approximately 4%) segments. Key revenue drivers include clinical trial backlog conversion and healthcare data subscription renewals. The company operates globally, with significant revenue contributions from the Americas, EMEA, and Asia-Pacific regions.
What is the assumed capital expenditure as a percentage of revenue in the IQVIA financial model?+
The financial model for IQVIA assumes capital expenditure (Capex) as a percentage of revenue to be approximately 4.9%. This investment primarily supports continuous enhancements to the proprietary CORE database and clinical trial management software platforms. A significant portion of this capex is allocated to capitalized software development, representing growth-oriented investment.
What are the key inputs considered when evaluating IQVIA's equity valuation in the financial model?+
The IQVIA financial model evaluates equity valuation by forecasting key operational drivers such as clinical trial backlog conversion and healthcare data subscription renewals. It also considers the allocation of free cash flow between debt repayment and share repurchases to determine the company's value and debt service capacity. The model covers a forecast horizon from FY2026 through FY2030.
Can I download an Excel financial model for IQVIA, and what is its forecast horizon?+
Yes, an Excel financial model for IQVIA is available for download, providing a detailed forecast of the company's financials. This model covers a forecast horizon from Fiscal Year 2026 through Fiscal Year 2030. It is designed to evaluate IQVIA's equity valuation and debt service capacity.
Why do goodwill and intangible assets represent such a large portion of IQVIA's total assets?+
Goodwill and intangible assets typically constitute 65% to 70% of IQVIA's total assets, reflecting the company's extensive acquisitive history. IQVIA is a serial bolt-on acquirer, focusing on niche data sets, healthcare technology, and specialized clinical capabilities. This strategy has led to a balance sheet dominated by these intangible assets.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Healthcare Services Company Financial Models
Browse another company in the same sector.
Cardinal Health
Cardinal Health is a global healthcare services and products company that provides customised solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centres, and clinical laboratories.
Cencora
Cencora, formerly AmerisourceBergen, is one of the largest global pharmaceutical sourcing and distribution services companies.
Charles River Laboratories
Charles River Laboratories is a leading early-stage contract research organisation (CRO) that provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts.
Quest Diagnostics
Quest Diagnostics is a leading provider of diagnostic information services, offering clinical testing that ranges from routine blood work to complex genetic and oncology diagnostics.
DaVita
DaVita is a leading provider of kidney care services, primarily operating outpatient dialysis centres for patients with end-stage renal disease, while also managing value-based care arrangements and an expanding international dialysis network.
HCA Healthcare
HCA Healthcare is the largest for-profit operator of health care facilities in the United States, managing 190 hospitals and approximately 2,400 ambulatory sites of care.
Henry Schein
Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, operating a global supply chain distributing over 300,000 products alongside software and e-services.
Labcorp
Laboratory Corporation of America Holdings (Labcorp) is a global life sciences company that provides comprehensive clinical laboratory and end-to-end drug development services.
Explore more Healthcare financial model templates.
